Alexander Biederstädt

Aug 22, 2024 | digitalcommons.library.tmc.edu | Alexander Biederstädt |Gohar Manzar |May Daher |Gohar Shahwar

The advent of cellular immunotherapy in the clinic has entirely redrawn the treatment landscape for a growing number of human cancers. Genetically reprogrammed immune cells, including chimeric antigen receptor (CAR)-modified immune effector cells as well as T cell receptor (TCR) therapy, have demonstrated remarkable responses across different hard-to-treat patient populations.

Jan 5, 2024 | nature.com | Mohsen Fathi |Ali Rezvan |Alexander Biederstädt |Ken Chen

Correction to: Nature Medicine https://doi.org/10.1038/s41591-022-02003-x, published online 29 September 2022. In the version of this article initially published, the competing interests section did not state that Paul Lin (The University of Texas MD Anderson Cancer Center) has an institutional financial conflict of interest with Takeda Pharmaceutical. The omission has been corrected in the HTML and PDF versions of the article. About this articleLi, Y., Basar, R., Wang, G. et al.